Literature DB >> 7213441

Cold dependent activation of complement in systemic lupus erythematosus. A unique cause for a discrepancy between clinical and laboratory parameters.

J P Atkinson, J C Gorman, J Curd, J F Hyla, M J Deegan, D F Keren, N I Abdou, S E Walker.   

Abstract

A 31-year-old woman with systemic lupus erythematosus (SLE) was studied because she developed markedly reduced total hemolytic complement activity at a time when her disease was clinically inactive. Functional assays demonstrated reduced activities of C1, C4, and C2, but normal concentrations of C3 and the terminal (C5-9) components were present. Antigenic concentrations of C1, C4, and C2 were normal. Plasma or serum obtained from blood allowed to clot at 37 degrees C had normal complement activity. Complement activity was depleted when the patient's serum was incubated in the cold. At reduced temperatures, the patient's serum (or purified IgG) depleted complement activity of normal human sera. A second patient with SLE was also demonstrated to have this same phenomenon. Cryoglobulins were not detectable in these patients. These data indicate that in vivo the patients' complement was normal and that the observed in vitro reduction was caused by cold dependent activation of the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7213441     DOI: 10.1002/art.1780240405

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2 in total

1.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  Pre-pregnancy serum complement C3 level is a predictor of preterm birth for pregnancies with systemic lupus erythematosus.

Authors:  Yuri Hiramatsu; Kentaro Isoda; Takuya Kotani; Eri Nakamura; Yumiko Wada; Youhei Fujiki; Shigeki Makino; Daisuke Fujita; Tohru Takeuchi
Journal:  Arthritis Res Ther       Date:  2021-05-12       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.